Combined methylphenidate and atomoxetine pharmacotherapy in attention deficit hyperactivity disorder

Basit Öğe Kaydı
dc.contributor.authorOzbaran, Burcu
dc.contributor.authorKose, Sezen
dc.contributor.authorYuzuguldu, Onur
dc.contributor.authorAtar, Burcu
dc.contributor.authorAydin, Cahide
dc.date.accessioned2019-10-27T22:59:15Z
dc.date.available2019-10-27T22:59:15Z
dc.date.issued2015
dc.departmentEge Üniversitesien_US
dc.description.abstractObjectves. Pharmacological treatment of attention deficit hyperactivity disorder (ADHD) includes stimulant and non-stimulant medications. Our purpose in this study is to investigate efficacy, safety and tolerability of combined methylphenidate and atomoxetine pharmacotherapy. Methods. We included 12 patients of the 824 patients with ADHD using methylphenidate and atomoxetine combined therapy between the years 2010 and 2014. Kiddie-SADS, Turgay DSM-IV Based Child and Adolescent Behavior Disorders Screening and Rating Scale, Child Behavior Checklist, Clinic Global Impression Scale Severity and Impression (CGIS-S-I) scales were used. Results. Patients were between the ages of 7 and 17 years. Before combined pharmacotherapy the CGIS-S score mean was 5.08. Mean CGIS-S score after the combined pharmacotherapy was 3.08 (P = 0.03; -2,980). The most common side effects were irritability (n = 5, 41.6%), appetite reduction (n = 3, 25%), palpitations (n = 2, 16.7%), headache (n = 1, 8.3%). Conclusons. Nine of these 12 patients showed significant improvement in their symptoms, combined therapy enhanced the effectiveness of monotherapy.en_US
dc.identifier.doi10.3109/15622975.2015.1051109en_US
dc.identifier.endpage624en_US
dc.identifier.issn1562-2975
dc.identifier.issn1814-1412
dc.identifier.issue8en_US
dc.identifier.pmid26223958en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage619en_US
dc.identifier.urihttps://doi.org/10.3109/15622975.2015.1051109
dc.identifier.urihttps://hdl.handle.net/11454/51757
dc.identifier.volume16en_US
dc.identifier.wosWOS:000365723500008en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofWorld Journal of Biological Psychiatryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectattention deficit hyperactivity disorderen_US
dc.subjectcombined therapyen_US
dc.subjectatomoxetineen_US
dc.subjectmethylphenidateen_US
dc.subjectpharmacotherapyen_US
dc.titleCombined methylphenidate and atomoxetine pharmacotherapy in attention deficit hyperactivity disorderen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu